Clinical Pipeline for Our Topical Muscle Relaxant with Antispasmodic Action
Advancing a Novel Drug for Muscle Spasms and Pain
Prima Innovations LLC is advancing a patented topical muscle relaxant with antispasmodic action designed to address muscle spasms at their source. Our lead investigational therapy represents a differentiated pharmaceutical approach to muscle spasm treatment, with development focused on localized skeletal muscle targeting rather than systemic central nervous system mechanisms.
As a pre-clinical stage pharmaceutical company, Prima Innovations is strategically progressing its development program through preclinical validation, regulatory planning, and preparation for formal human studies. Our pipeline is centered on a single high-value asset with broad potential applications across musculoskeletal and spasticity-related conditions.
PI-101 (Topical Antispasmodic)
Centered on a single high-value asset with broad potential applications across musculoskeletal and spasticity-related conditions.
Dsicovery
Formulation & IP
Preclinical
Proof-of-concept
IND-Enabling
Regulatory Prep
Unmet Need
First-in-Human
PI-101 (Topical Antispasmodic)
Centered on a high-value platform technology with broad potential applications across musculoskeletal and spasticity-related conditions.
Discovery
Proof of Principle
Formulation & IP
Preclinical
Proof-of-concept
IND-Enabling
Regulatory Prep
Unmet Need
First-in-Human
Lead Candidate Overview
Our investigational therapy is being developed as a pharmaceutical-grade topical skeletal muscle relaxant formulated for dermal administration. The compound is designed to produce an antispasmodic effect within muscle tissue, offering a distinct scientific approach compared to many traditional oral muscle relaxant drugs.
Targeted therapeutic areas under evaluation include:

- Acute musculoskeletal pain relief
- Medication for painful muscle spasms
- Back pain muscle relaxant applications
- Neck pain muscle spasm relief
- Spasticity treatment medication opportunities
By focusing on localized muscle activity, our program aims to support effective pain relief while advancing a differentiated safety and tolerability profile pending clinical validation.
Development Status
Prima Innovations has completed foundational preclinical work designed to establish mechanistic rationale and proof-of-concept for its topical muscle relaxant platform. These activities have included:
- Evaluation of pharmacodynamic response in muscle contraction models
- Assessment of dermal penetration and tissue exposure
- Preliminary safety and tolerability studies
- Formulation optimization for pharmaceutical-grade consistency
The company is currently preparing for the next stage of development, which includes regulatory engagement and planning for formal clinical evaluation.
As with all investigational therapies, advancement through clinical phases will require regulatory review and successful demonstration of safety and efficacy in human trials.
Regulatory Strategy
Prima Innovations is committed to a structured regulatory pathway consistent with FDA and international standards. The company is developing its clinical strategy with the goal of:

- Defining appropriate initial study populations
- Establishing dose-ranging parameters
- Identifying safety and pharmacokinetic endpoints
- Designing trials aligned with musculoskeletal and pain-related indications
The topical route of administration presents unique regulatory considerations, particularly related to dermal absorption, systemic exposure levels, and localized tissue effects. Our regulatory planning incorporates these factors to ensure scientific rigor and compliance.
Engagement with regulatory authorities will guide the final design of first-in-human studies and subsequent clinical phases.
Intellectual Property
The global demand for muscle spasm treatment and acute musculoskeletal pain relief continues to grow due to aging populations, increased musculoskeletal injuries, and chronic pain prevalence. Current therapeutic options include oral skeletal muscle relaxants, injectables, and non-prescription topical products, yet few pharmaceutical agents directly target muscle tissue through localized pharmacologic mechanisms.
Prima Innovations’ topical muscle relaxant drug is positioned to address this gap. Once clinical development confirms safety and efficacy, our therapy will represent a new category of antispasmodic medication.
Our long-term vision includes:
- Expansion into multiple muscle-related indications
- Strategic partnerships with pharmaceutical companies
- Licensing or co-development opportunities
- Scalable commercial manufacturing strategy
Market Opportunity and Strategic Vision
The global demand for muscle spasm treatment and acute musculoskeletal pain relief continues to grow due to aging populations, increased musculoskeletal injuries, and chronic pain prevalence. Current therapeutic options include oral skeletal muscle relaxants, injectables, and non-prescription topical products, yet few pharmaceutical agents directly target muscle tissue through localized pharmacologic mechanisms.

Prima Innovations’ topical muscle relaxant drug is positioned to address this gap. If clinical development confirms safety and efficacy, our therapy may represent a new category within antispasmodic medication.
Our long-term vision includes:
Scalable commercial manufacturing strategy
Licensing or co-development opportunities
Strategic partnerships with pharmaceutical companies
Scalable commercial manufacturing strategy
Our investigational compound is being developed to exhibit antispasmodic effect at the muscle level rather than relying primarily on central nervous system modulation. This scientific strategy represents a meaningful advancement in muscle relaxant drug development.
Upcoming Milestones
Prima Innovations continues to build momentum within the life sciences investment community. In January 2026, the company will present at the Biotech Showcase during JPM Week in San Francisco. COO and Co-Founder Dr. Mandar Shah will provide updates on the development roadmap, intellectual property strategy, and scientific foundation of the investigational therapy.
Near-term objectives include:
- Completion of regulatory preparatory activities
- Finalization of clinical study protocols
- Continued engagement with investors and strategic partners
- Advancement toward first-in-human evaluation

Each milestone is designed to de-risk the program and enhance long-term asset value.
Frequently Asked Questions
Q:
Is the therapy currently in clinical trials?
Prima Innovations is advancing toward formal clinical evaluation. The investigational therapy has not yet received regulatory approval.
Q:
Is the therapy currently in clinical trials?
Prima Innovations is advancing toward formal clinical evaluation. The investigational therapy has not yet received regulatory approval.
Q:
What differentiates this muscle relaxant drug from others?
Our therapy is being developed as a topical muscle relaxant with antispasmodic action intended to act locally within skeletal muscle rather than primarily through central nervous system pathways.
Q:
What indications are being prioritized?
Development planning includes muscle spasm treatment, acute musculoskeletal pain relief, back and neck muscle spasm conditions, and potential spasticity treatment medication applications.
Q:
Are partnership opportunities available?
Yes. Prima Innovations actively welcomes discussions with pharmaceutical partners, institutional investors, and strategic collaborators.
Investor & Partnership Inquiries
We invite investors and strategic partners to connect with us to learn more about our topical muscle relaxant platform and clinical development strategy.
Thank you for contacting us.We’ll get back to you as soon as possible.
We got it.
Ready to begin?
You don’t have to take the next step alone.
Reaching out is the first step.
